Yiqun Yu

ORCID: 0000-0002-8771-1969
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Essential Oils and Antimicrobial Activity
  • Antifungal resistance and susceptibility
  • Lung Cancer Treatments and Mutations
  • Antimicrobial Peptides and Activities
  • Natural Compounds in Disease Treatment
  • Family Support in Illness
  • Hip and Femur Fractures
  • Quinazolinone synthesis and applications
  • PI3K/AKT/mTOR signaling in cancer
  • Cancer-related cognitive impairment studies
  • Colorectal Cancer Treatments and Studies
  • Lipoproteins and Cardiovascular Health
  • Fungal Plant Pathogen Control
  • Advancements in Transdermal Drug Delivery
  • Diabetes Treatment and Management
  • Bone Metabolism and Diseases
  • Pharmacological Effects and Toxicity Studies
  • Bone health and osteoporosis research
  • Chronic Myeloid Leukemia Treatments
  • Shoulder Injury and Treatment
  • Cancer survivorship and care
  • Drug Transport and Resistance Mechanisms
  • Drug-Induced Adverse Reactions
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmacovigilance and Adverse Drug Reactions

Fudan University
2019-2024

Minhang District Central Hospital
2017-2024

Shanghai Genon Biological Products (China)
2023

Eye & ENT Hospital of Fudan University
2023

Shanghai Ninth People's Hospital
2020-2022

Zhejiang Provincial People's Hospital
2021

Weatherford College
2020

Wenzhou Medical University
2018

First Affiliated Hospital of Wenzhou Medical University
2018

Florida College
1997

Atorvastatin and its lactone form metabolite are reported to be associated with statin-induced myopathy (SIM) such as myalgia life-threatening rhabdomyolysis. Though the rhabdomyolysis is not common during statin therapy, incidence will significantly increase due pharmacokinetic drug-drug interactions (DDIs) inhibitor drugs which inhibit atorvastatin's lactone's metabolism hepatic uptake. Thus, quantitative analysis of DDIs atorvastatin cytochrome P450 3A4 (CYP3A4) organic anion-transporting...

10.1016/j.biopha.2019.109416 article EN Biomedicine & Pharmacotherapy 2019-09-10

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or esophageal junction adenocarcinoma. predominantly metabolized by CYP3A4/5, followed CYP2D6. The present study aimed to evaluate potential drug-drug interaction (DDI) and drug-disease (DDZI) risks apatinib in Chinese volunteers. Methods: Modeling simulation were conducted using Simcyp Simulator. input parameters...

10.3389/fphar.2021.780937 article EN cc-by Frontiers in Pharmacology 2021-11-22

In vitro interaction of osthol (Ost) and fluconazole (FLC) was investigated against 11 fluconazole-resistant clinical isolates Candida albicans. Synergistic activities were determined using the checkerboard microdilution assay. The results agar diffusion test confirmed synergistic interaction. We used an enteric material Eudragit S100 for preparation Ost nanoparticle (Ost-NP) to improve oral bioavailability, biological activity Ost. physicochemical characteristics Ost-S100-NP revealed with...

10.1080/21505594.2017.1356503 article EN cc-by Virulence 2017-08-10

Osteoporosis is a clinically common metabolic disease, especially in postmenopausal women. Tai Chi might be beneficial osteoporosis patients. This study will performed to examine the effects of on bone mineral density osteoporosis.We search electronical databases and hand-searching journals or reference lists. The screening data extraction carried out by 2 investigators independently. primary outcome (lumbar spine, Ward's triangle, trochanter, proximal femur, femoral neck, total hip)....

10.1097/md.0000000000021928 article EN cc-by-nc Medicine 2020-09-01

Several pharmacological agents, such as chloroquine/hydroxychloroquine, have been promoted for COVID-19 treatment or pre-exposure prophylaxis. However, no comprehensive evaluation of the safety these possible agents is available, and urgently needed. The purpose this study was to investigate risks cardiac adverse events associated with pharmacotherapies COVID-19, including certain antimalarial, antiviral, antibiotic drugs. We conduced retrospective pharmacovigilance analyses US Food Drug...

10.1007/s40801-021-00229-8 article EN cc-by-nc Drugs - Real World Outcomes 2021-02-10

Objective. To determine whether arthrographic distention combined with manipulation for frozen shoulder provides additional benefits. Methods. A total of 180 participants from five clinical centers pain and stiffness in predominantly 1 >3 months entered the study, 165 completed study. The control group was treated alone, treatment underwent after resting 5 minutes following distention. Patients were followed up at one two weeks three six months. For evaluation, shoulder-specific...

10.1155/2022/1562358 article EN cc-by BioMed Research International 2022-02-13

Aim: It has been found that the co-administration of nifedipine with apatinib could cause exposure changes in vivo. But, whether this pharmacokinetic drug-drug interaction (DDI) between and enhance antihypertensive effect nifedipine, causing sever blood pressure was unknown. Therefore, aim present study to conduct pharmacokinetic/pharmacodynamic (PK/PD) modelling evaluate on nifedipine. Thus, results guide these two drugs clinic. Methods: A physiologically-based (PBPK) model first developed...

10.3389/fphar.2022.970539 article EN cc-by Frontiers in Pharmacology 2022-08-26

Ensartinib (X-396) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine inhibitor (TKI) indicated for the treatment of ALK-positive patients with locally advanced or metastatic non-small cell lung cancer. Although in vitro experiments and molecular docking suggested its potential as cytochrome P450 inhibitor, no further investigation clinical trials have been conducted to assess drug-drug interaction (DDI) risk. In this study, we series elucidate inhibition mechanism ensartinib....

10.1124/dmd.123.001373 article EN Drug Metabolism and Disposition 2023-08-29

Abstract Aims The present study aimed to quantitatively investigate the potential drug–drug interaction (DDI) mechanism between meropenem (MEPM) and valproic acid (VPA). Methods In study, we firstly developed a physiologically based pharmacokinetic (PBPK) model of MEPM VPA. verified PBPK was then used DDI effect genetic polymorphisms acylpeptide hydrolase (APEH) on also evaluated. Results our simulation, plasma concentration hydrolysate VPAG decreased 63% when combined with MEPM. Total VPA...

10.1111/bcp.16350 article EN British Journal of Clinical Pharmacology 2024-11-22
Coming Soon ...